CLINICAL TRIAL SUMMARY

MDACC Study No:SWOG S0816 (clinicaltrials.gov NCT No: NCT00822120)
Title:A Phase II Trial of Response-Adapted Therapy of Stage III/IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Principal Investigator:Michelle A. Fanale
Treatment Agent:Adriamycin; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; FDGPET; None; Prednisone; Procarbazine; Vincristine; Vincristine Sulfate
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if switching from a
standard chemotherapy combination to a more intensive experimental combination,
based on imaging scans, will improve response to treatment in patients with
Hodgkin lymphoma (HL). The safety of this experimental chemotherapy
combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Adriamycin
Bleomycin
Cyclophosphamide
Dacarbazine
Doxorubicin
Etoposide
FDGPET
None
Prednisone
Procarbazine
Vincristine
Vincristine Sulfate
Treatment Location:Both at MDACC & Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:none
Supported By:Southwest Oncology Group
Return Visit:Screening; D1, D15, D29, D43, D53, D57, D71, D 78, D85, D99, D113, D120, D127,
D141, D155, D162, D186, D190, D276, D365
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults